Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eMonarcHER
2020-004035-24Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib plus physician's choice endocrine therapy with Placebo plus physician's choice endocrine therapy (2 arms). Primary endpoint: invasive disease-free survival. Started Feb 2021; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-004035-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004035-24.